BBIO
Price
$32.52
Change
-$1.09 (-3.24%)
Updated
Dec 8, 6:59 PM EST
75 days until earnings call
CYTO
Price
$0.41
Change
-$0.10 (-19.61%)
Updated
Dec 8, 6:59 PM EST
Ad is loading...

Compare trend and price BBIO vs CYTO

Header iconBBIO vs CYTO Comparison
Open Charts BBIO vs CYTOBanner chart's image
BridgeBio Pharma
Price$32.52
Change-$1.09 (-3.24%)
Volume$648.24K
CapitalizationN/A
Altamira Therapeutics
Price$0.41
Change-$0.10 (-19.61%)
Volume$5.02M
CapitalizationN/A
View a ticker or compare two or three
BBIO vs CYTO Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
BBIO vs. CYTO commentary
Dec 10, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBIO is a StrongBuy and CYTO is a Hold.

COMPARISON
Comparison
Dec 10, 2023
Stock price -- (BBIO: $32.52 vs. CYTO: $0.41)
Brand notoriety: BBIO and CYTO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BBIO: 108% vs. CYTO: 50%
Market capitalization -- BBIO: $5.18B vs. CYTO: $1.76M
BBIO [@Biotechnology] is valued at $5.18B. CYTO’s [@Biotechnology] market capitalization is $1.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BBIO’s FA Score shows that 1 FA rating(s) are green whileCYTO’s FA Score has 1 green FA rating(s).

  • BBIO’s FA Score: 1 green, 4 red.
  • CYTO’s FA Score: 1 green, 4 red.
According to our system of comparison, both BBIO and CYTO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BBIO’s TA Score shows that 6 TA indicator(s) are bullish while CYTO’s TA Score has 6 bullish TA indicator(s).

  • BBIO’s TA Score: 6 bullish, 4 bearish.
  • CYTO’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both BBIO and CYTO are a good buy in the short-term.

Price Growth

BBIO (@Biotechnology) experienced а +5.11% price change this week, while CYTO (@Biotechnology) price change was +28.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10161.68%. For the same industry, the average monthly price growth was +8.48%, and the average quarterly price growth was +27.10%.

Reported Earning Dates

BBIO is expected to report earnings on Feb 22, 2024.

CYTO is expected to report earnings on Nov 17, 2022.

Industries' Descriptions

@Biotechnology (+10161.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for BBIO with price predictions.
OPEN
A.I.dvisor published
a Summary for CYTO with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
BBIO($5.18B) has a higher market cap than CYTO($1.76M). BBIO YTD gains are higher at: 326.772 vs. CYTO (-91.548). CYTO has higher annual earnings (EBITDA): -22.48M vs. BBIO (-535.91M). BBIO has more cash in the bank: 543M vs. CYTO (49.6K). CYTO has less debt than BBIO: CYTO (3.47M) vs BBIO (1.74B). BBIO has higher revenues than CYTO: BBIO (9.43M) vs CYTO (120K).
BBIOCYTOBBIO / CYTO
Capitalization5.18B1.76M294,265%
EBITDA-535.91M-22.48M2,384%
Gain YTD326.772-91.548-357%
P/E RatioN/AN/A-
Revenue9.43M120K7,857%
Total Cash543M49.6K1,094,758%
Total Debt1.74B3.47M50,043%
FUNDAMENTALS RATINGS
CYTO: Fundamental Ratings
CYTO
OUTLOOK RATING
1..100
26
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
17

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BBIOCYTO
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 11 days ago
85%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TBNK9.570.70
+7.89%
Territorial Bancorp
GHG3.720.02
+0.54%
GreenTree Hospitality Group Ltd
HRMY31.00-0.05
-0.16%
Harmony Biosciences Holdings
NNN40.75-0.54
-1.31%
NNN Reit
AGRI0.59-0.06
-9.37%
AgriFORCE Growing Systems Ltd

BBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with ARGX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then ARGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BBIO
1D Price
Change %
BBIO100%
-3.24%
ARGX - BBIO
51%
Loosely correlated
-0.94%
ABOS - BBIO
45%
Loosely correlated
-1.42%
AXON - BBIO
44%
Loosely correlated
+0.45%
ARRY - BBIO
43%
Loosely correlated
-0.44%
ORMP - BBIO
40%
Loosely correlated
-0.44%
More